Harpoon Therapeutics (HARP) Value Adjusted for Debt and Cash

Harpoon Therapeutics (HARP) is building a defensive moat through patents on unique TriTAC molecules, securing funding via partnerships with pharma behemoths. The development model relies on the monetization of intellectual property, which eliminates the costs associated with launching production facilities. This price chart reflects an Enterprise Value of . Now part of Merck, the company is developing a line of antibodies to combat solid tumors.

For a fundamental valuation of Harpoon Therapeutics (HARP), it is critical to understand the real business value, accounting not only for market capitalization but also for debt obligations net of liquid reserves. An analysis of the Enterprise Value (EV) determines the actual cost of acquiring the company and its innovative TriTAC platform, where the chart reflects the balance between leveraged capital and resources for immunotherapy development.